This has been demonstrated in previous studies using CED of OT101, a TGFB2-specific synthetic phosphorothioate antisense oligodeoxynucleotide (S-ODN), to treat recurrent/refractory WHO grade 3 anaplastic astrocytoma (R/R AA) patients, which resulted in a sustained partial response (PR) or complete response (CR) in 14 out of 27 patients (51.9%) [74]. Here, TGFB2 is linked to anaplastic astrocytoma.